

# NATIONAL JEWISH HEALTH

## *Curriculum Vitae*

Name: Jennifer L. Taylor-Cousar

Professional Degrees: MD, MSCS, ATSF

### I. ACADEMIC HISTORY

#### A. COLLEGES AND UNIVERSITIES ATTENDED

2015	Master of Science, Clinical Science University of Colorado Denver, CO
1998	Doctor of Medicine Duke University Medical Center Durham, NC
1993	Bachelor of Arts, Human Biology Stanford University Stanford, CA

#### B. BOARD CERTIFICATION

2009-present	Colorado State Medical License - #48114
2008-present	ABP, Subspecialty in Pediatric Pulmonology- #622107
2006-present	ABIM, Subspecialty in Pulmonary Disease - #224593
2006-2010	New Mexico State Medical License - #MD2006-0579
2004-2014	American Board of Internal Medicine - #224593
2002-2012	American Board of Pediatrics - #622107
2002-2006	North Carolina State Medical License - #2002-01186

### II. PROFESSIONAL POSITIONS

2019-present	Professor (tenured) Co-Director (2015-)/CF TDN Director (2017-), Adult CF Program Departments of Internal Medicine and Pediatrics Pulmonary Divisions National Jewish Health
--------------	--

Denver, CO

2019-present Professor  
Departments of Internal Medicine and Pediatrics  
Pulmonary Divisions  
University of Colorado  
Aurora, CO

2014-present Medical Staff  
Pulmonary Medicine  
Saint Joseph Hospital  
Denver, CO

2014-present Associate Professor (tenured, 2019)  
Co-Director (2015-)/CF TDN Director (2017-), Adult CF Program  
Departments of Internal Medicine and Pediatrics  
Pulmonary Divisions  
National Jewish Health  
Denver, CO

2014-present Associate Professor  
Departments of Internal Medicine and Pediatrics  
Pulmonary Divisions  
University of Colorado  
Aurora, CO

2009-present Medical Staff  
Department of Pulmonology  
Children's Hospital Colorado  
Aurora, CO

2009-2014 Assistant Professor  
Associate Adult CF Program Director (2011-2014)  
Departments of Medicine and Pediatrics  
Pulmonary Divisions  
National Jewish Health  
Denver, CO

2009-2014 Assistant Professor  
Departments of Medicine and Pediatrics  
Pulmonary Divisions  
University of Colorado  
Aurora, CO

2006-2009 Assistant Professor  
Adult Cystic Fibrosis Program Director, Associate CF Center Director

Departments of Internal Medicine and Pediatrics  
Pulmonary Divisions  
University of New Mexico  
Albuquerque, NM

2002-2006 Fellowship  
Adult and Pediatric Pulmonary Medicine  
Duke University Medical Center  
Durham, NC

1998-2002 Internship and Residency  
Internal Medicine and Pediatrics  
Duke University Medical Center  
Durham, NC

### III. ACADEMIC HONORS

#### NATIONAL

2018 Quality Care Award: Recognizing Outstanding QI Processes and Accomplishments  
Cystic Fibrosis Foundation  
Bethesda, MD

2018 ATS Fellow, Inaugural Class  
American Thoracic Society  
New York, NY

2018-2020 Best Doctors in America  
National Jewish Health  
Denver, CO

2018-2020 America's Best Physicians  
National Jewish Health  
Denver, CO

2017 Founder's Award  
United States Adult Cystic Fibrosis Association  
Indianapolis, IN

2015-2017 America's Top Doctors  
National Jewish Health  
Denver, CO

2014 Professional Leadership Selectee, AAMC  
Mid-Career Women Faculty Professional Development Seminar

Austin, TX

- 2013 Faculty Member with Best Communication Skills (CF Team Nomination)  
Mountain West CF Consortium Meeting  
Salt Lake City, UT
- 2009 Professional of the Year Award,  
Cystic Fibrosis Research Institute  
Redwood City, CA
- 2009 Professional Leadership Selectee, AAMC  
Early Career Women Faculty Professional Development Seminar  
Washington, DC
- 2005 2<sup>nd</sup> Place, Fellows' Clinical Research Presentations  
Respiratory Disease Young Investigators Forum  
Academic Research Coalition/National Jewish Health/University of North Carolina
- 2005 Carl Storm Underrepresented Minority Fellow  
Gordon Research Conference
- 2004 American College of Chest Physicians Fellows Travel Award  
ACCP Conference
- 2004 American Academy of Pediatric Pulmonology Fellows Travel Award  
Pediatric Pulmonary Conference
- 1999 National Institutes of Health/National Medical Association Travel Award  
NMA Conference

#### LOCAL/REGIONAL

- 2018 Clinical Quality Award  
National Jewish Health  
Denver, CO
- 2017 Clinical Quality Award

Updated November 2019

	National Jewish Health Denver, CO
2017	Faculty Citizen of the Year Award Nominee National Jewish Health Denver, CO
2016	Physician of the Year, Colorado Society for Respiratory Care Denver, CO
2015	Science Transforming Life Award National Jewish Health Denver, CO
2015	Clinical Quality Award National Jewish Health Denver, CO
2015	Physician of the Year Nominee Saint Joseph Hospital Denver, CO
2014	Viola Vestal Coulter Research Fellow Award National Jewish Health Denver, CO
2012	Outstanding Medicine Junior Faculty Award Nominee National Jewish Health Denver, CO
2008	Clinical Trials Center New Investigator of the Year Award University of New Mexico Albuquerque, NM
2006	Pulmonary Fellowship Scientific Achievement Award Duke University Durham, NC
2003	Cystic Fibrosis Foundation Clinical Fellow Duke University Durham, NC
2001	Hubert Scholar, Duke University International Health Program Durham, NC

1997	Best Medical Student Abstract, Department of Anesthesiology Academic Evening Duke University, Durham, NC
1996-1997	Four Schools Physician Scientist Research Scholar Duke University, Durham, NC
1994-1998	Dean's Tuition Scholar Duke University, Durham, NC

IV. PROFESSIONAL AFFILIATIONS

2019	Member, European Respiratory Society
2017-present	Member, European CF Society
2003-present	Member, American Thoracic Society

V. COMMITTEE PARTICIPATION AND OTHER SERVICE ACTIVITIES

A. HOSPITAL

2019	Search Committee, Department of Medicine Chair National Jewish Health Denver, CO
2019	Research Compensation Plan Committee National Jewish Health Denver, CO
2018	Chair, CF Disease State Training Symposium National Jewish Health Denver, CO
2017-present	CF Therapeutics Development Center Director National Jewish Health Denver, CO
2017-present	Medical Director, Clinical Research Services National Jewish Health Denver, CO
2017-2018	Medical Executive Council

	National Jewish Health Denver, CO
2015-present	Executive Champion, Diversity and Inclusion Council National Jewish Health Denver, CO
2014-present	Research Advisory Council National Jewish Health Denver, CO
2014-present	Medical Executive Council, NJH representative Exempla-St. Joseph's Hospital Denver, CO
2014-2015	Co-Chair, Clinical Research Development at ESJH Committee National Jewish Health Denver, CO
2014	NJH-ESJH Physician and Clinical Integration Team National Jewish Health Denver, CO
2013-2014	Research Strategic Planning Committee National Jewish Health Denver, CO
2013-2014	Chair, Clinical and Translational Research Section (Co-Chair 2011) National Jewish Health Denver, CO
2013	Search Committee, Internal Medicine-Pediatrics Director University of Colorado Aurora, CO
2012	Chair, Cystic Fibrosis Advanced Disease State Training Symposium, National Jewish Health Denver, CO
2012-2013	Search Committee, Pediatric Pulmonary Chair National Jewish Health Denver, CO
2011	Chair, Cystic Fibrosis Advanced Disease State Training Symposium, National Jewish Health

2010-2014	Infection Control Committee National Jewish Health Denver, CO
2008-2009	Co-Chair, Minority Women in Medicine Committee University of New Mexico Albuquerque, NM
2008-2009	Child Health Research Action Group University of New Mexico Albuquerque, NM
2006-2007	Member, Minority Women in Medicine Committee University of New Mexico Albuquerque, NM

#### B. UNIVERSITY

2017-present	Committee to Advance Gender Equity, Compensation Equity Task Force Department of Medicine University of Colorado Aurora, CO
2011-present	CCTSI Co-Pilot Grant Reviewer University of Colorado Aurora, CO

#### C. NATIONAL/INTERNATIONAL

2019	International Advisory Meeting on CF Clinical Research Development North American CF Conference, Nashville, TN
2019-present	Chair, Cystic Fibrosis Foundation Women's Health Consortium Steering Committee
2019-present	Member, Clinical Research Advisory Board, Cystic Fibrosis Foundation
2018-present	Member, Cystic Fibrosis Therapeutics Development Network Clinical Research Executive Committee
2018-present	Member, CF Therapeutics Clinical Strategy Steering Committee (Santhera)
2018-2019	Member, Scientific Advisory Committee, American Thoracic Society



2018	Member, Cystic Fibrosis Foundation Clinical Research Award Plus (CRA+) Committee
2018-present	Chair, PTI-428 Phase III Development Steering Committee (Proteostasis Therapeutics)
2018-present	Member, CF Therapeutics Clinical Strategy Steering Committee (Proteostasis Therapeutics)
2017-present	Co-Chair, Next Generation CFTR Modulator Development Program Steering Committee (Vertex Pharmaceuticals)
2016-present	Expert Advisor, CF Contraceptive Registry Development Group
2016-present	International Orangutan Veterinary Advisory Group
2015	Chair and Moderator, Mountain West CF Consortium Conference Denver, CO
2013-2016	Co-Chair (Lead Chair, 2015-2016) Clinical Year in Review Committee American Thoracic Society International Conference
2013	Member, Strategic Initiative Action Committee Communications Team Cystic Fibrosis Foundation
2012	Invited participant, Respiratory Working Group International Orangutan Health Workshop
2011-2018	Protocol Review Committee, Expert Reviewer (2015-2018) Cystic Fibrosis Therapeutics Development Network
2009	Chair, Mountain West CF Consortium Conference Santa Fe, NM
2009-2018	Program Committee, Clinical Problems Assembly American Thoracic Society
2008-2012	Health Policies Committee American Thoracic Society
2007-present	Mountain West Cystic Fibrosis Consortium Steering Committee

#### D. COMMUNITY ACTIVITIES

2019-present	Health and Genetics Committee, Member Rhodesian Ridgeback Club of the United States
2014-present	Therapy Dog International Member Ronald McDonald House, Teller Elementary Denver, CO
2011-present	Pulmonary Consultant, Great Apes Denver Zoo Denver, CO
2010-present	Medical Advisor/Member Colorado Cystic Fibrosis Foundation Advisory Board
2010-present	Board Member, Vice President (2011-2017) Colorado Rhodesian Ridgeback Club Denver, CO
2010-2016	Team Leader, Cystic Fibrosis Stair Climb Challenge National Jewish Health Denver, CO
2010-2014	Stanford Alumni Interviewer
2007-2009	Medical Advisor/Board Member New Mexico Cystic Fibrosis Foundation Advisory Board

## VI. REVIEW ACTIVITIES

Current	<i>Ad hoc</i> reviewer American Journal of Respiratory Cell and Molecular Biology Annals of the American Thoracic Society Chest BMC Pulmonary Medicine Clinical Medicine Insights Cochrane Cystic Fibrosis & Genetic Disorders Group Drugs of Today European Respiratory Reviews Expert Reviews in Molecular Medicine Journal of Cystic Fibrosis Pediatric Pulmonology PLOS One Science Advances Therapeutic Advances in Respiratory Disease
Previous	Human Immunology Western Regional Meeting

## VII. TEACHING ACTIVITIES

### A. TEACHING ATTENDING

2013-present	Medicine-Pediatrics Medical Student Rotation preceptor National Jewish Health Denver, CO
2012-present	Outpatient Pediatric Pulmonary Clinic National Jewish Health Denver, CO
2010-2014	Inpatient Pulmonary Consult Service University of Colorado Aurora, CO
2009-present	Inpatient CF Service National Jewish Health-Saint Joseph's Hospital Aurora, CO
2009-present	Outpatient CF Clinic National Jewish Health Denver, CO
2006-2009	Inpatient Pulmonary Consult Service University of New Mexico
2006-2009	Outpatient CF clinic University of New Mexico

### B. GRADUATE, MEDICAL SCHOOL, UNDERGRADUATE, AND HIGH SCHOOL LECTURES

2019	Cystic Fibrosis: Great Strides and Future Directions Pulmonary Fellows Conference University of Colorado/National Jewish Health Denver, CO
2018	NIH Grant Review-Mock Study Section CLSC 7101 Grant Writing I University of Colorado Aurora, CO
2016	Animals in Research

West High School (Utah)

2016	Update on Cystic Fibrosis Clinical Care and Research Internal Medicine/Pediatrics Conference University of Colorado Aurora, CO
2008	Genetics of Cystic Fibrosis University of New Mexico
2008	Adult Cystic Fibrosis Management Central New Mexico Community College
2008	Topics in Pediatric Pulmonary Disease University of New Mexico
2007-2009	Asthma Case Wrap-Up University of New Mexico
2007-2008	Cystic Fibrosis Case Wrap-Up University of New Mexico
2007	Cystic Fibrosis 101 University of New Mexico
2006	Asthma in Adult & Pediatric Patients Emergency Medical Services Academy University of New Mexico
2006	Hemoptysis in Adult & Pediatric Patients Emergency Medical Services Academy University of New Mexico
2004	Cigarettes and Second Hand Smoke Duke University Medical Center Durham, NC
2003-2004	Lung Transplantation in Cystic Fibrosis Medical Student CPC Lecture Series Duke University Medical Center Durham, NC
C. MENTORING	
2019-present	Daniel Beswick, MD

	CFF Clinical Research Award “Impact of TC CFTR Therapy on Sinus Disease in CF: Quantitative CT and PROs” 2019 Assistant Professor, University of Colorado
2019-present	Jeff King, MD CFF DIGEST Award, 2019 Assistant Professor, National Jewish Health
2018-present	Alexander Gifford, MD, FCCP CF Therapeutics Development Center Mentored PI Associate Professor, Dartmouth-Hitchcock Medical Center,
2018-present	Shijing Jia, MD Assistant Professor, University of Michigan
2018-present	Derek Low, MD CFF Fellowship, 2019 “An observational study of the effects on clinical outcomes of extended access program of Vertex triple combination therapy” Adult Pulmonary Fellow, University of Colorado
2017-present	Ann Grancelli, MD Assistant Professor, National Jewish Health
2017-present	Sherstin Lommatzsch, MD Assistant Professor, National Jewish Health
2014-present	Core Faculty, Med-Peds Residency Training Program University of Colorado School of Medicine
2016-2018	Kenneth Hunt, MS CF Research Coordinator/Pre-Med Student Current position: Medical student, Ochsner School of Medicine. AUS
2013-2016	Caroline Jones, BS Research coordinator/pre-RN student Current position: BSN at St. Joseph Hospital Denver, CO
2012-2017	Theresa Heynekamp, MD Pulmonary Fellow Program in Adult Care Excellence Award, CFF September 2012 Current Position: Associate Professor, University of New Mexico
2011-2016	Nauman Chaudary, MD Assistant Professor, University of Mississippi

Program in Adult Care Excellence Award, CFF July 2011  
Current position: Adult CF Program Director, UVA

- 2011-2014      George M. Solomon, MD  
Pulmonary Fellow  
Fellowship project: Nasal potential difference measurement in subjects with non-CF bronchiectasis  
Current position: Assistant Professor, University of Alabama, Birmingham
- 2010-2011      Andrew Elder, BA  
High school student  
Research project: REDCaP Project Database Creation  
Current position: Product Designer at Palantir Technologies
- 2007-2011      Elena Griego, BS  
Medical student  
Medical student research project: The Effect of sildenafil on the pH of exhaled breath condensate in cystic fibrosis  
Current position: Clinical Instructor, University of Washington, Seattle
- 2006-present    Karen Miller, MD,  
Pulmonary Fellow  
Program in Adult Care Excellence Award, CFF June 2008.  
Current Position: Adult CF Program Director, Idaho Pulmonary Associates

## VIII. RESEARCH GRANTS AND CONTRACTS

### A. CURRENT FUNDING

- |                           |  |
|---------------------------|--|
| Principal Investigator    | Title: CF Women's Health Consortium Steering Committee<br>Sponsor: Cystic Fibrosis Foundation<br>09/1/2019-08/31/2021                            |
| Co-Principal Investigator | Title: Impact of TC CFTR Therapy on Sinus Disease in CF: Quantitative CT and PROs<br>Sponsor: Cystic Fibrosis Foundation<br>08/01/2019-7/31/2021 |
| Co-Principal Investigator | Title: Evaluation of Predictors of Maternal-Fetal Outcomes in Cystic Fibrosis<br>Sponsor: Cystic Fibrosis Foundation<br>08/01/2019-7/31/2022     |

Co-Investigator	Title: Assessment of Contraceptive Safety and Effectiveness among Women with Cystic Fibrosis Sponsor: Cystic Fibrosis Foundation 08/01/2019-7/31/2022
TDN Site Principal Investigator	Title: VX-18-561-101 A Phase 2, randomized, double-blind study to evaluate the efficacy and safety of VX-561 in subjects aged 18 years and older with Cystic Fibrosis Sponsor: Vertex Pharmaceuticals Incorporated 05/15/2019-05/31/2020
Co-Principal Investigator	Title: Mechanisms of exercise intolerance in Cystic Fibrosis: Role of PDE5 inhibition Sponsor: Cystic Fibrosis Foundation/Augusta U
Principal Investigator	Title: CF Therapeutics Development Center Sponsor: Cystic Fibrosis Foundation 1/1/2019-12/31/2019 *RENEWED ANNUALLY*
Co-Investigator	Title: Sexual and Reproductive Health in Adult Women with Cystic Fibrosis (PI: Traci Kazmerski, MD) Sponsor: University of Pittsburgh 10/2/2018-9/30/2020
Private Donation	Title: Orangutan Respiratory Disease Role: Principal Investigator 11/20/2018-12/31/2019
Private Donation	Title: Adult Cystic Fibrosis Clinical Trial Research Role: Principal Investigator 10/30/2018-present
TDN Site Principal Investigator	Title: VX17-445-105: Open Label extension study of VX-445 Combination Therapy in Subjects Who Are Heterozygous for the <i>F508del</i> Mutation and a Minimal Function Mutation (F/MF) and Homozygous for the <i>F508del</i> Mutation (F/F) Role: Site Principal Investigator \$108,081 (direct) \$35,991 (Indirect) 09/11/2018-12/31/2020
TDN Site Principal Investigator	Title: PTI-808-01: A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-

808 in Healthy Adult Subjects and in Adults with Cystic Fibrosis  
Sponsor: Proteostasis Therapeutics, Inc.  
Role: Site Primary Investigator  
06/01/2018-08/01/2019

TDN Site Principal Investigator Title: CHaractERizing CFTR Modulated Changes in Sweat Chloride and their Association with Clinical Outcomes (CHEC-SC) (PI: Zemanick)  
Role: Site Principal Investigator  
Sponsor: Seattle Children's Hospital  
2/14/2018-10/31/2019

Private Donation Title: Adult Cystic Fibrosis Clinical Trial Research  
Role: Principal Investigator  
12/1/2017-present

TDN Site Principal Investigator Title: PTI-801-01: A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects with Cystic Fibrosis  
Role: Site Principal Investigator  
Sponsor: Proteostasis Therapeutics, Inc.  
11/17/2017-present

TDN Site Principal Investigator Title: Multicenter validation of predictive sputum biomarkers in CF (PI: Ted Liou, MD)  
Role: Site Principal Investigator  
Sponsor: University of Utah  
4/1/2014-9/30/2019

TDN Site Principal Investigator Title: G551D Observational Study-Expanded to Additional Genotypes and Extended to Long-Term Follow-up (GOALe<sup>2</sup>) (PI: Steve Rowe, MD)  
Role: Site Principal Investigator  
02/17/2014-2/1/2020

## B. PENDING FUNDING

TDN Site Principal Investigator Title: A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a



	Gating or Residual Function Mutation (F/G and F/RF Genotypes) Role: Site Principal Investigator Contract pending
TDN Site Principal Investigator	Title: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)
TDN Site Principal Investigator	Title: EL-012, Phase 2 Study of ELX-02 in Cystic Fibrosis patients with nonsense mutations Role: Site Principal Investigator Contract pending

### C. PAST FUNDING

Co-Investigator	Title: Improving the Management of Chronic Respiratory Disease in Captive Bornean Orangutans ( <i>Pongo Pygmaeus</i> ) Utilizing Cystic Fibrosis Therapies in an Orangutan Rehabilitation Program In East Kalimantan, Indonesia (PI: Nancy Lung, VMD) Role: Co-Investigator Sponsor: AAZV 07/01/2018-08/30/2019
TDN Site Principal Investigator	Title: VX17-445-102: Phase 3, Randomized, Double-Blind, Controlled, Studies Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects Who Are Heterozygous for the <i>F508del</i> Mutation and a Minimal Function Mutation (F/MF) Role: Site Principal Investigator 06/15/2018-7/31/2019
TDN Site Principal Investigator	Title: VX17-445-103: Phase 3, Randomized, Double-Blind, Controlled, Studies Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects Who Are Homozygous for the <i>F508del</i> Mutation (F/F) followed by an Open Label extension study Role: Site Principal Investigator 7/12/2018-7/31/2019

TDN Site Principal Investigator	Title: A Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT) (PI: Rowe) Role: Site Principal Investigator Sponsor: Seattle Children's Hospital 8/1/2016-7/31/2019
<b>National Principal Investigator</b>	Title: PTI-428-06 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of PTI 428 in combination with tezacaftor-ivacaftor in Subjects Aged 12 Years and Older with Cystic Fibrosis Role: Lead and Site Principal Investigator 6/27/2018-7/31/2019
<b>Global Principal Investigator</b>	Title: VX16-445-001: A Phase 1/2 Study of VX-445 in Healthy Subjects with Cystic Fibrosis Role: Global Lead and Site Principal Investigator Sponsor: Vertex Pharmaceuticals Incorporated 06/26/2017- 6/30/2019
TDN Site Principal Investigator	Title: VX16-809-120: A Post-approval Observational Study to Evaluate the Long-term Effectiveness and Safety of Orkambi in US Patients Who Completed Study VX12-809-105 Part A Sponsor: Vertex Pharmaceuticals Incorporated Role: Site Primary Investigator Contract pending 06/22/2018-06/30/2019
TDN Site Principal Investigator	Title: VX16-661-114: Phase 3b, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Safety, Efficacy and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who Are Homozygous for the <i>F508del-CFTR</i> Mutation Role: Site Principal Investigator Sponsor: Vertex Pharmaceuticals Incorporated 04/11/2017-4/30/2019
NICK14YO	Title: CF Therapeutics Development Center Role: Principal Investigator Sponsor: Cystic Fibrosis Foundation 1/1/2018-12/31/2018 *RENEWED ANNUALLY*

TAYLOR16Y6	Title: CF TDN PI Protected Effort Role: Principal Investigator Sponsor: Cystic Fibrosis Foundation Therapeutics 1/1/2018-12/31/2018
Private Donation	Title: Genetics of Orangutan Lung Disease Role: Principal Investigator 12/31/2017-12/31/2018
TDN Site Principal Investigator	Title: VX14-661-110: A Phase 3, Open-Label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the <i>F508del-CFTR</i> Mutation Role: Site Principal Investigator Sponsor: Vertex Pharmaceuticals Incorporated 10/5/2015-10/4/2018
TDN Site Principal Investigator	Title: CTX-4430-CF-201: EMPIRE CF: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients with Cystic Fibrosis Sponsor: Celtaxsys, Inc. Role: Site Principal Investigator 01/01/2016-7/7/2018
TDN Site Principal Investigator	Title: Vertex VX15-440-101: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older with Cystic Fibrosis Role: Site Principal Investigator Sponsor: Vertex Pharmaceuticals Incorporated 11/4/2016-08/31/2018
CC009-17AD	Title: CF Center Award Role: Co-Director Sponsor: Cystic Fibrosis Foundation 7/1/2017-6/30/2018
TDN Site Principal Investigator	Title: VX16-809-117: A Multicenter, Retrospective, Real-World Observational Study on Orkambi Use Sponsor: Vertex Pharmaceuticals Incorporated

	<p>Role: Site Principal Investigator 02/02/2017-01/31/2018</p>
Site Principal Investigator	<p>Title: Building a Contraceptive Registry for Women with Complex Medical Conditions (PI: Emily Godfrey) Role: Site Principal Investigator Sponsor: Society of Family Planning 10/3/2017-10/2/2018</p>
TDN Site Principal Investigator	<p>Title: BAY-63-2521/17020: Multi-center, randomized, double-blind, placebo-controlled phase 2 study to assess the safety, tolerability and early signs of efficacy of tid orally administered <i>BAY63-2521</i> in adult DF508 homozygous Cystic Fibrosis patients Sponsor: Bayer HealthCare AG Role: Site Principal Investigator 10/14/2014-01/31/2018</p>
Private Donation	<p>Title: Genetics of Orangutan Lung Disease Role: Principal Investigator 12/14/2016-12/31/2017</p>
NICK14YO	<p>Title: CF Therapeutics Development Center Role: Principal Investigator Sponsor: Cystic Fibrosis Foundation 7/1/2017-12/31/2017 (RENEWED ANNUALLY)</p>
TAYLOR16Y6	<p>Title: CF TDN PI Protected Effort Role: Principal Investigator Sponsor: Cystic Fibrosis Foundation Therapeutics 1/1/2017-12/31/2017</p>
TDN Site Principal Investigator	<p>Title: VX14-661-108: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination with Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the <i>F508del-CFTR</i> Mutation, and a Second Allele With a <i>CFTR</i> Mutation Predicted to Have Residual Function Role: Site Principal Investigator Sponsor: Vertex Pharmaceuticals Incorporated 04/17/2015-12/31/2017</p>

<b>Global Co-Principal Investigator</b>	<p>Title: VX14-661-106: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the <i>F508del-CFTR</i> Mutation</p> <p>Sponsor: Vertex Pharmaceuticals Incorporated</p> <p>Role: Global Lead and Site Principal Investigator</p> <p>\$61,742 (direct); \$20,560 (indirect)</p> <p>04/14/2015 -07/14/2017</p>
TDN Site Principal Investigator	<p>Title: VX14-809-106: A Phase 3b, Open Label Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Cystic Fibrosis and Advanced Lung Disease, Homozygous for the <i>F508del CFTR</i> Mutation</p> <p>Sponsor: Vertex Pharmaceuticals Incorporated</p> <p>Role: Site Principal Investigator</p> <p>03/23/2015-11/30/2017</p>
TDN Site Principal Investigator	<p>Title: VX14-661-107: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the <i>F508del-CFTR</i> Mutation and With a Second <i>CFTR</i> Mutation That Is Not Likely to Respond to VX-661 and/or Ivacaftor Therapy (<i>F508del/NR</i>)</p> <p>Sponsor: Vertex Pharmaceuticals Incorporated</p> <p>Role: Site Principal Investigator</p> <p>08/14/2015-07/17/2017</p>
Gilead CF Scholar	<p>Title: Genetic and phenotypic characterization of CF airway disease in non-human primates</p> <p>Role: Principal Investigator</p> <p>Sponsor: Gilead Sciences, Inc.</p> <p>5/14/2013-5/14/2017</p>
TDN Site Principal Investigator	<p>Title: N9115-2CF-06 (SNO-7): A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis who are Heterozygous for <i>F508del-CFTR</i> and a</p>

	<p>Gating Mutation Approved for Use and Being Treated with Ivacaftor (Kalydeco™)  Sponsor: Nivalis Therapeutics, Inc  Role: Site Principal Investigator  04/06/2016-02/13/2017</p>
TDN Site Principal Investigator	<p>Title: N91115-2CF-05 (SNO-6): A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients with Cystic Fibrosis who are Homozygous for the <i>F508del-CFTR</i> Mutation and Being Treated with lumacaftor/ivacaftor  Sponsor: Nivalis Therapeutics, Inc.  Role: Site Principal Investigator  12/09/2015-02/13/2017</p>
<b>National Principal Investigator</b>	<p>Title: N91115-2CF-03 (SNO-4): A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Study of N91115 to Evaluate Safety and Pharmacokinetics in Patients with Cystic Fibrosis Patients Homozygous for the <i>F508del-CFTR</i> Mutation  Sponsor: N30 Pharmaceuticals, Inc.  Role: National Lead and Site Principal Investigator  02/05/2015-06/16/2015</p>
TDN Site Principal Investigator	<p>Title: N91115-1PK-02 (SNO-3): A Phase 1, Open-Label Study Evaluating the Pharmacokinetics of N91115 in Cystic Fibrosis Patients  Sponsor: N30 Pharmaceuticals, Inc.  Role: Site Principal Investigator  10/15/2014-10/30/2015</p>
Private Donation	<p>Title: Genetics of Orangutan Lung Disease  Role: Principal Investigator  2015-2016</p>
1K23HL103801-01A1	<p>Title: Use of Phosphodiesterase Inhibitors to Evaluate the Pathobiology of Cystic Fibrosis Lung Disease  Role: Principal Investigator  Sponsor: NIH  2011-2016</p>
TDN Site Principal Investigator	<p>Title: VX12-809-105; A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term</p>

	<p>Treatment Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation.  Role: Site Principal investigator  11/01/2013-06/16/2016</p>
TDN Site Principal Investigator	<p>Title: VX12-809-103; A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Lumacaftor Monotherapy and in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation.  Role: Site Principal investigator  2013-2014</p>
TDN Site Principal Investigator	<p>Title: VX12-809-102; A Phase 2, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Lumacaftor Monotherapy and Lumacaftor and Ivacaftor Combination Therapy in Subjects with Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation.  Role: Site Principal investigator  2013-2014</p>
TDN Site Principal Investigator	<p>Title: Safety and Pharmacokinetic Study of N6022 in Subjects with Cystic Fibrosis Homozygous for the F508del-CFTR mutation  Role: Principal investigator  2013-2014</p>
TDN Site Principal Investigator	<p>Title: G551D Observational Study (GOAL study)  Role: Site Principal Investigator  2012-2014</p>
TAYLOR-COUSAR CCTSI	<p>Title: Effects of sildenafil on CFTR-dependent ion transport activity  Role: Principal Investigator  2011-2014</p>
TDN Site Principal Investigator	<p>Title: An Open-Label, Rollover Study to Evaluate the Long-Term Safety and Efficacy of VX-770 in</p>

	Subjects with Cystic Fibrosis (Vertex VX08-770-105) Role: Principal Investigator 2010-2012
LHOM8847 NIH	Title: Effects of sildenafil on CFTR-dependent ion transport activity Role: Principal Investigator 2010-2012
TDN Site Principal Investigator	A Randomized, Double Blind, Parallel Group, Placebo Controlled 28- Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis Role: Principal Investigator 2009-2011
TDN Site Principal Investigator	A Phase 3, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects with Cystic Fibrosis and the G551D Mutation (VX08-770-102) Role: Principal Investigator 2009-2011
C073-TDC09Y CFFT	Title: Therapeutics Development Network Expansion-University of New Mexico Role: Principal Investigator 2009
TAYLOR08AO CFFT	Title: The Role of Sildenafil in CF Lung Disease Role: Principal Investigator 2008-2012
BXVM5217 NIH	Title: The Role of Phosphodiesterase Inhibitors in Mild-Moderate Cystic Fibrosis Lung Disease Role: Principal Investigator 2008-2010
TDN Site Principal Investigator	Title: Protocol Number S245.3.128 – An open label, multi-center study to assess the safety and tolerability of Pancrelipase delayed release capsules in infants and children less than seven years of age with pancreatic exocrine insufficiency due to cystic fibrosis Role: Principal Investigator – University of New Mexico



	2008-2009
UNMexico	Cystic Fibrosis Foundation Role: Principal Investigator 2008-2009
TDN Site Principal Investigator	Title: Protocol Number S245.3.127 – A double-blind, Randomized, multi-center, cross-over study to assess the efficacy and safety of Pancrelipase delayed release capsules 12,000 in subjects 7-11 years old with pancreatic exocrine insufficiency due to cystic fibrosis Role: Principal Investigator – University of New Mexico 2008-2009
Clinical Investigator	Title: Asuragen CF Expand Study Project Role: Subinvestigator – University of New Mexico 2008-2009
TDN Site Principal Investigator	Title: Protocol EA-US-205-0111 – Expanded access program for Aztreonam Lysine for inhalation in patients with cystic Fibrosis and <i>Pseudomonas aeruginosa</i> airway infection who have limited treatment options and are at risk for disease progression. Role: Principal Investigator – University of New Mexico 2008-2009
Pediatric Research Committee Grant	Title: The role of phosphodiesterase inhibitors in mild-moderate CF lung disease. Role: Principal Investigator 2007-2009
University of New Mexico Clinical Translational Science Center Career Development Award	Title: The role of phosphodiesterase inhibitors in mild-moderate CF lung disease Role: Principal Investigator 2007-2009
TDN Site Principal Investigator	Title: Genetic Modifiers of Cystic Fibrosis – Multi-Center study investigating the role of genetic modifiers in CF through enrollment of twins and siblings with CF. Role: Principal Investigator – University of New Mexico 2007-2009
TDN Site Principal Investigator	Title: Protocol Number TR02-106 – Multidose safety and Tolerability study of liposomal amikacin for inhalation

	(Arikace™) in cystic fibrosis patients with chronic infections due to <i>Pseudomonas Aeruginosa</i> . Role: Principal Investigator – University of New Mexico 2007-2009
TDN Site Principal Investigator	Title: Topic Z3877g Pulmozyme Study – Multicenter, Phase IV study investigating the effect of Pulmozyme on exercise tolerance in patients with severe CF lung disease. Role: Principal Investigator – University of New Mexico 2007-2008
Site Principal Investigator	Title: Multicenter investigation of the role of genetic modifiers in Cystic fibrosis lung disease. Role: Principal Investigator – University of New Mexico 2006-2009
CR073-CRF06A CFFT	Title: Clinical Research Facilitation Award – Expand CF clinical research capability at University of New Mexico. Role: Principal Investigator 2006-2008
WNMY4293 NIH	Title: Genetic modifiers in cystic fibrosis lung disease – Investigating the role of genetic modifiers in severity of cystic fibrosis lung disease. Role: Principal Investigator 2005-2007
1 F32 HL82207-01 NIH/NHLBI	Title: Genetic modifiers in cystic fibrosis lung disease – investigating the role of genetic modifiers in severity of cystic fibrosis lung disease. Role: Principal Investigator 2005-2006
G050001972 GSK	Title: Genetic modifiers in cystic fibrosis lung disease Role: Principal Investigator 2005-2006
Hubert Fellowship	Title: International Health Scholar Program Investigated the incidence, impact and testing options for HIV in a referral hospital in Tanzania. Role: Principal Investigator 2001
Four Schools Research Scholarship	Title: Four Schools Physician-Scientist training program Grant – investigated the role of heme oxygenase-1 in hyperoxic lung injury.

Role: Principal Investigator  
1996-1997

## IX. BIBLIOGRAPHY

### A. PUBLICATIONS IN REFEREED JOURNALS

1. Heijerman HGM, \* McKone EF\*, Downey DG, Braeckel E, Rowe SM, Tullis E, Mall M, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, **Taylor-Cousar JL\***, and McCoy K\* on behalf of the VX17-445-103 Trial Group. Efficacy and safety of the elexacaftor/tezacaftor/ivacaftor combination regimen in people with cystic fibrosis homozygous for the *F508del* mutation: a double-blind, randomised, phase 3 trial. **\*equal contributions** *Lancet*. 2019 Oct 30. pii: S0140-6736(19)32597-8. doi: 10.1016/S0140-6736(19)32597-8. PMID: 31679946
2. Middleton PG\*, Mall MA\*, Drevinek P, Lands LC, McKone EF, Polineni D, Ramsey BW, **Taylor-Cousar JL**, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM\*\* and Jain R\*\* for the VX17-445-102 Study Group. Elexacaftor-Tezacaftor-Ivacaftor for CF with a Single Phe508del Mutation. *New Eng J Med*. 2019. *In press*
3. Downey DG and **Taylor-Cousar JL**. Challenges and opportunities in the development of future CFTR modulator options for people with CF J Cyst Fibros. 2019 Oct 28. pii: S1569-1993(19)30917-8. doi: 10.1016/j.jcf.2019.10.010. [Epub ahead of print] PMID: 31672556
4. **Taylor-Cousar JL**, Mall MA, Ramsey BW, McKone EF, Tullis, E, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F and Rowe SM. Development of CFTR Modulators in Triple Combination. *ERJ Open Research* 2019 5: 00082-2019; **DOI**: 10.1183/23120541.00082-2019
5. Liou TG, Adler FR, Argel N, Asfour F, Brown P, Chatfield BA, Daines C, Durham D, Francis JA, Glover B, Heynekamp T, Hoidal JR, Jensen JL, Keogh R, Kopecky C, Lechtzin N, Li Yanping, Lysinger J, Molina O, Nakamura C, Pacer KA, Poch K, Quittner AL, Radford P, Redway A, Sagel S, Sprandel S, **Taylor-Cousar JL**, Vroom J, Yoshikawa R, Clancy JP, Elborn JS, Olivier KN and Cox DR. Design of a Prospective Multicenter Observational Study of Sputum Biomarkers of Inflammation in Cystic Fibrosis. *BMC Med Res Methodol*. 2019 Apr 26;19(1):88. doi: 10.1186/s12874-019-0705-0. PMID: 31027503
6. Somayaji R, Russel R, Cogen JD, Goss CH, Nick SE, Saavedra MT, **Taylor-Cousar JL**, Nick JA, Nichols DP. Oral azithromycin use and the recovery of lung function from pulmonary exacerbations treated with intravenous tobramycin or colistin in adults with cystic fibrosis. *Ann Am Thorac Soc*. 2019 Mar 6. doi: 10.1513/AnnalsATS.201811-773OC. [Epub ahead of print] PMID:30840835

7. Pohl K, Nichols DP, **Taylor-Cousar JL**, Saavedra MT, Strand MJ, Nick JA, Bratcher PE. Corticosteroid use and increased CXCR2 levels on leukocytes associate with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation. *PLOS One*. 2018 Dec 12;13(12):e0209026. doi: 10.1371/journal.pone.0209026 PMID: 30540818
8. Bratcher PE, Hunt KC, Pickard K, **Taylor-Cousar JL (corresponding author)**. Positive Clinical Response to Ivacaftor Treatment in an individual with the CFTR genotype F508del/V456A. *J Cystic Fibrosis J Cyst Fibros*. 2018 Oct 19. pii: S1569-1993(18)30865-8. doi: 10.1016/j.jcf.2018.10.008. [Epub ahead of print] PMID: 30348612
9. Keating D, Sass L Burr L, Daines C, Rowe S, Savage J, Simard C, Xuan F, Van Goor F, Robertson S, McKee C, Waltz D, Marigowda G, and **Taylor-Cousar JL (corresponding author)**. VX-445 in Combination with Tezacaftor-Ivacaftor in Phe508del Homozygous and Heterozygous Patients with Cystic Fibrosis. *N Engl J Med* 2018; 379:1612-1620 DOI: 10.1056/NEJMoa1807120 PMID: 30334692
10. Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone E, Plant B, Paris D, Ramsey B, **Taylor-Cousar JL**, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM. Triple Combination of VX-659/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and One or Two *F508del-CFTR* Alleles. *N Engl J Med* 2018 Oct 25;379(17):1599-1611. doi: 10.1056/NEJMoa1807119 PMID: 303334693
11. Saavedra MT, Quon BS, Faino A, Caceres SM, Poch KR, Sanders LA, Malcolm KC, Nichols DP, Sagel SD, **Taylor-Cousar JL**, Leach SM, Strand M, Nick JA. Whole Blood Gene Expression Profiling Predicts Severe Morbidity and Mortality in Cystic Fibrosis. A 5-year Follow-up Study. *Ann Am Thorac Soc*. 2018 doi: 10.1513/AnnalsATS.201707-527OC PMID: 29425066
12. **Taylor-Cousar JL (corresponding author)**, Jain M, Barto TL, Haddad T, Akinson J, Tian S, Tang R, Marigowda G, Waltz D, Pilewski J on behalf of the VX-14-809-106 investigator group. Lumacaftor/ivacaftor (LUM/IVA) in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR: a 24-wk open label study. *J Cyst Fibros*. Nov 8, 2017. DOI: 10.1016/j.jcf.2017.09.012 PMID: 29126871
13. **Taylor-Cousar JL**, Munck A, McKone EF, van der Ent CK, Moeller A, Lekstrom-Himes J, Lu Y, McKee C, Wang LT, Simard C, Ingenito EP, and Elborn JS for the **EVOLVE and EXPAND Study Groups**. Tezacaftor-Ivacaftor in Phe508del Homozygous Patients with Cystic Fibrosis. *New Eng J Med*. November 3, 2017; 377(21):2013-2023 DOI: 10.1056/NEJMoa1709846. PMID 29099344
14. Rowe SM, Daines C, Ringshausen F, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, and Davies JC for the **EVOLVE**

- and EXPAND Study Groups.** Tezacaftor-Ivacaftor in Residual Function Heterozygotes with Cystic Fibrosis. *New Eng J Med.* November 3, 2017 DOI: 10.1056/NEJMoa1709847 PMID: 29099333
15. Donaldson SH, Solomon GM, Zeitlin PL, Flume PA, Casey A, McCoy K, Zemanick ET, Mandagere A, Troha JM, Shoemaker SA, Chmiel JF, **Taylor-Cousar JL.** Pharmacokinetics and safety of Cavosonstat (N91115) in adults with cystic fibrosis homozygous for F508del-CFTR. *J Cyst Fibros.* 2017 May;16(3):371-379. PMID:28209466
  16. Heltshe SL, Godfrey EM, Josephy T, Aitken ML, **Taylor-Cousar JL.** Pregnancy Incidence Among Cystic Fibrosis Women in the Era of CFTR Modulators. *J Cyst Fibros.* 2017 Feb 9. pii: S1569-1993(17)30015-2. doi: 10.1016/j.jcf.2017.01.008. PMID: 28190780
  17. Nichols DP, Happoldt CL, Bratcher PE, Caceres SM, Chmiel JF, Malcolm KC, Saavedra MT, Saiman L, **Taylor-Cousar JL,** Nick JA. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. *J Cyst Fibros.* 2017 May;16(3):358-366.. doi: 10.1016/j.jcf.2016.12.003. PMID: 28025037
  18. **Taylor-Cousar JL (corresponding author),** Janssen JS, Wilson A, St. Clair CG, Pickard KM, Jones MC, Brayshaw SJ, Chacon CS, Barboa CM, Sontag MK, Accurso FJ, Nichols DP, Saavedra MT, and Nick JA. Glucose <200mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes. *J of Diabetes Res* 2016 Article ID 1527932, doi:10.1155/2016/1527932 PMID: 27999822
  19. Nick JA, Caceres SM, Kret JE, Poch KR, Strand M, Faino AV, Nichols DP, Saavedra MT, **Taylor-Cousar JL,** Geraci MW, Burnham EL, Fessler MB, Suratt BT, Abraham E, Moss M, Malcolm KC. Extremes of Interferon-stimulated Gene Expression Associate with Worse Outcomes in the Acute Respiratory Distress Syndrome *PLOS One.* 2016; 11(9): e0162490. PMID: 27606687
  20. Stringer E, Cossaboon C, Han S, and **Taylor-Cousar JL.** Sinusitis, bronchiectasis and flatus in a Sumatran orangutan (*Pongo Abelii*): Could this be cystic fibrosis? *J Zoo Wildl Med.* 2016 Mar;47(1):347-50. doi:10.1638/2015-0058.1. PMID:27010300
  21. Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen SM, Waltz D, and Boyle MP for the **TRAFFIC and TRANSPORT study groups.** Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del *CFTR.* *N Engl J Med.* 2015. doi:10.1056/NEJMoa1409547 PMID: 25981758

22. **Taylor-Cousar JL (corresponding author)**, Nikknian M, Gilmartin G and Pilewski J. Effect of Ivacaftor in patients with cystic fibrosis, and a G551D-CFTR mutation: expanded access program in the United States. *J Cyst Fibros*. 2015 Feb 11. PMID: 2568022
23. **Taylor-Cousar JL (corresponding author)**, St. Clair C, Jones M, Nichols DP, Saavedra MT, Curran-Everett D, Nick JA, Accurso FJ. Pharmacokinetics and Tolerability of Oral Sildenafil in Adults with Cystic Fibrosis Lung Disease. *J Cyst Fibros*. 2015 Mar;14(2):228-36. doi:10.1016/j.jcf.2014.10.006. PMID: 25466700
24. McKone EF, Borowitz D, Drevinek P, Griese M, Konstan MW, Wainwright C, Ratjen F, Sermet-Gaudelus I, Plant B, Munck A, Jiang Y, Gilmartin G, Davies JC; **VX08-770-105 (PERSIST) Study Group**. Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST). *Lancet Respir Med*. 2014 Nov;2(11):902-10. doi:10.1016/S2213-2600(14)70218-8. PMID: 25311995
25. Ferril G, Nick J, Getz A, Barham H, Saavedra M, **Taylor-Cousar J**, Nichols D, Curran-Everett Douglas, Kingdom T, Ramakrishnan V. Comparison of radiographic and clinical characteristics of low-risk and high-risk CF genotypes. *Int Forum Allergy Rhinol*. 2014 Nov;4(11):915-20. doi:10.1002/alr.21412. PMID:25224556
26. Caceres C, Malcolm K, **Taylor-Cousar JL**, Nichols DP, Saavedra MT, Bratton D, Moskowitz S, Burns J and Nick JA. Enhanced in Vitro Formation and Antibiotic Resistance of Non-attached *Pseudomonas aeruginosa* Aggregates through Incorporation of Neutrophil Products. *Antimicrob Agents Chemother*. 2014 Nov;58(11):6851-60. doi:10.1128/AAC.03514-14. PMID: 25182651
27. Rowe SM, Heltshe SL, Gonska T, Donaldson SH, Borowitz D, Gelfond D, Sagel SD, Khan U, Mayer-Hamblett N, Van Daltsen JM, Joseloff E, Ramsey BW; **GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network**. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. *Am J Respir Crit Care Med*. 2014 Jul 15;190(2):175-84. doi: 10.1164/rccm.201404-0703OC. PMID: 24927234
28. Nick JA, Moskowitz SM, Chmiel JF, Forssen AV, Kim SH, Saavedra MT, Saiman L, **Taylor-Cousar JL**, and Nichols DP. Azithromycin May Antagonize Inhaled Tobramycin when Targeting *Pseudomonas aeruginosa* in Cystic Fibrosis. *Ann Am Thorac Soc*. 2014 Mar;11(3):342-50. doi:10.1513/AnnalsATS.201310-352OC. PMID: 24476418
29. Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR and Rodman D. **VX09-809-102 Study Group**. A CFTR corrector

- (lumacaftor) and a CFTR potentiator (ivacafor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. *Lancet Respir Med.* 2014; 2(7):527-538. PMID: 24973281
30. Nick JA, Sanders LA, Ickes B, Briones NJ, Caceres SM, Malcolm KC, Brayshaw SJ, Chacon CS, Barboa CM, Jones MC, StClair C, **Taylor-Cousar JL**, Nichols DP, Sagel SD, Strand M, and Saavedra MT. Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis. *Thorax* doi:10.1136/thoraxjnl-2012-202278. PMID: 23783371
  31. Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, Goss CH, Lymp J, Minic P, Quittner AL, Rubenstein RC, Young KR, Saiman L, Burns JL, Govan JR, Ramsey B, Gupta R; **Arikace Study Group**. Phase II studies of nebulised Arikace in CF patients with *Pseudomonas aeruginosa* infection. *Thorax.* 2013;68(9):818-25. doi:10.1136/thoraxjnl-2012-202230. PMID: 23749840
  32. Malcolm KC, Nichols EM, Caceres SM, Kret JE, Martiniano SL, Sagel SD, Chan ED, Caverly L, Solomon GM, Reynolds P, **Taylor-Cousar JL**, Nichols DP, Saavedra MT, Nick JA. Mycobacterium abscessus induces a pattern of neutrophil activation that promotes pathogen survival. *PLoS One.* 2013;8(2):e57402. doi:10.1371/journal.pone.0057402. Epub 2013 Feb 25. PMID: 23451220
  33. Nichols DP, Caceres S, Caverly L, Fratelli C, Kim SH, Malcolm KC, Saavedra M, Solomon G, **Taylor-Cousar JL**, Moskowitz SM, Nick JA. Azithromycin reduces *Pseudomonas aeruginosa* lung infection from cutaneous thermal injury and alters the effects of other anti-Pseudomonas antibiotics. *J Surg Res.* 2013 Feb 24. pii: S0022-4804(13)00088-7. doi:10.1016/j.jss.2013.02.003. PMID: 23478086
  34. Neda Rasouli N, Seggelke S, Gibbs J, Hawkins RM, Casciano ML, Cohlmiya E, Wang C, Pereira R, Hsia E, **Taylor-Cousar JL**, and Draznin B. Cystic fibrosis-related diabetes: inpatient management of 121 patients during 410 admissions. *J Diabetes Sci Technol.* 2012; 6(5):1038-1044. PMID: 23063029
  35. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; **VX08-770-102 Study Group**. *N Engl J Med.* 2011 Nov 3;365(18):1663-72. doi:10.1056/NEJMoa1105185. PMID: 22047557
  36. Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, **Taylor-Cousar JL**, Saavedra MT, Randell SH, Vasil ML, Burns JL, Moskowitz SM and Nick JA. Neutrophil extracellular trap (NET)-mediated response to *Pseudomonas aeruginosa* occurs independent of cystic fibrosis transmembrane conductance regulator function. *PLoS One.* 2011; 6(9):e23637. PMID: 21909403

37. Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, Picard CG, Young RL, Nichols DP, Janssen JS, Huitt GA, Iseman MD, Daley CL, **Taylor-Cousar JL**, Accurso FJ, Saavedra MT and Sontag MK. Effects of Gender and Age of Diagnosis on Disease Progression in Long-term Cystic Fibrosis Survivors. *Am J Resp Crit Care Med*. 2010 Sep 1;182(5):614-26. PMID: 20448091
38. Bartlett JR, Friedman KJ, Ling SC, Pace RG, Bell SC, Bourke B, Castaldo G, Castellani C, Cipolli M, Colombo C, Colombo JL, Debray D, Fernandez A, Lacaille F, Macek M Jr, Rowland M, Salvatore F, Taylor CJ, Wainwright C, Wilschanski M, Zemková D, Hannah WB, Phillips MJ, Corey M, Zielenski J, Dorfman R, Wang Y, Zou F, Silverman LM, Drumm ML, Wright FA, Lange EM, Durie PR, Knowles MR; **Gene Modifier Study Group**. Genetic modifiers of liver disease in cystic fibrosis. *JAMA*. 2009 Sep 9;302(10):1076-83. doi:10.1001/jama.2009.1295. PMID: 19738092
39. **Taylor-Cousar JL**, Zariwala MA, Burch LH, Pace RG, Drumm ML, Calloway H, et al. Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity. *PLoS One*. 2009;4(1):e4270. PMCID: 2627933. PMID: 19169360
40. Ornatowski W, Poschet JF, Perkett E, **Taylor-Cousar JL**, Deretic V. Elevated furin levels in human cystic fibrosis cells result in hypersusceptibility to exotoxin A-induced cytotoxicity. *J Clin Invest*. 2007;117(11):3489-97. PMCID: 2030457. PMID: 17948127
41. Poschet JF, Timmins GS, **Taylor-Cousar JL**, Ornatowski W, Fazio J, Perkett E, et al. Pharmacological modulation of cGMP levels by phosphodiesterase 5 inhibitors as a therapeutic strategy for treatment of respiratory pathology in cystic fibrosis. *Am J Physiol Lung Cell Mol Physiol*. 2007;293(3):L712-9. PMID: 17586695
42. **Taylor JL** and Palmer SM. Mycobacterial Abscesses Chest Wall and Pulmonary Infection in a Cystic Fibrosis Lung Transplant Recipient. *J Heart Lung Transplant*. 2006;25:985-8. PMID: 16890122
43. Ole-Nguyaine S, Crump JA, Kibiki GS, Kiang K, **Taylor J**, Schimana W, et al. HIV-associated morbidity, mortality and diagnostic testing opportunities among inpatients at a referral hospital in northern Tanzania. *Ann Trop Med Parasitol*. 2004;98(2):171-9. PMID: 15035727
44. **Taylor JL**, Quinones Maymi DM, Sporn TM, McAdam HP and Wahidi MW. Multiple Lung Modules in a Woman with a History of Melanoma. *Respiration*. 2003;70:544-48. PMID: 14665785
45. **Taylor JL**, Carraway MS, Piantadosi CA. Lung-specific induction of heme oxygenase-1 and hyperoxic lung injury. *Am J Physiol*. 1998;274(4 Pt 1):L582-90. PMID: 9575877



46. Carraway MS, Ghio AJ, **Taylor JL**, Piantadosi CA. Induction of ferritin and heme oxygenase-1 by endotoxin in the lung. *Am J Physiol*. 1998;275(3 Pt 1):L583-92. PMID: 9728054

## B. INVITED REVIEWS AND EDITORIALS

1. Shteinberg M and **Taylor-Cousar JL**. Impact of CFTR modulator use on outcomes in people with severe CF lung disease. *Submitted Aug 2019*
2. Lommatzsch S and **Taylor-Cousar JL (corresponding author)**. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects. *Thorax*. 2019 Jan-Dec; 67(1):e1-e7. doi: 10.1136/thorax-2018-212442. PMID: 31027466
3. Heltshe, SL and **Taylor-Cousar JL (corresponding author)**. Let's Talk about Sex: Behaviors, Experience and Health Care Utilization in Young Women with CF. *J Cyst Fibros*. 1-DEC-2017 DOI information: 10.1016/j.jcf.2017.11.006
4. **Taylor-Cousar JL** and Elborn JS. S14.1 Advances in Treating Patients Homozygous for F508del. *Pediatr Pulmonol* 2017; 52, Suppl 47: 173-175.
5. Kuk K, **Taylor-Cousar JL (corresponding author)**. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. *Thorax*. 2015 Dec;9 (6):313-26. Review. PMID:2641682
6. **Taylor-Cousar JL**, VonKessel KA, Young R, Nichols DP. The potential use of anti-inflammatories for the treatment of Cystic Fibrosis. *J Inflamm Res*. 2010;3:61-74. PMID: 22096358
7. **Taylor-Cousar JL**. Hypoventilation in Cystic Fibrosis. *Semin Respir and Crit Care Med*. 2009;30(3):293-302. PMID: 19452389
8. **Taylor JL** and Palmer SM. A Critical Care Perspective on Immunotherapy in Lung Transplantation. *J Intensive Care Med*. 2006;21(6):327-344. PMID: 17095497

## C. OTHER PUBLICATIONS

1. **Taylor-Cousar, JL** and Jia, S. New Directions in CF Therapies. eCysticFibrosis Review. Vol 8, Issue 12. <https://elit.dkbmed.com/issues/40>

2. **Taylor-Cousar, JL.** Clinical Considerations: New Anti-inflammatories and New CFTR Modulators. *eCysticFibrosis Review*. Vol 8, Issue 13.  
<https://elit.dkbmed.com/issues/45>
3. **Taylor-Cousar, JL.** Cystic Fibrosis Foundation Webcast: New Developments in Clinical Research-Infections. 2018. Available from:  
<https://www.cff.org/Research/About-Our-Research/New-Developments-in-Research/>
4. **Taylor-Cousar JL** and Elborn S. Advances in Treating Patients Homozygous for F508del. *Pediatr Pulmonol* 2017; 5, Suppl 47: S14.1.
5. **Taylor-Cousar JL**, Jain M, Barto TL, Haddad T, Akinson J, Tian S, Tang R, Marigowda G, Waltz D, Pilewski J on behalf of the VX-14-809-106 investigator group. Lumacaftor/ivacaftor (LUM/IVA) in patients with cystic fibrosis and advanced lung disease homozygous for F508del-CFTR: a 24-wk open label study. *CF Research News*. 2017. Available from: <https://www.ecfs.eu/content/cf-research-news>
6. **Taylor-Cousar, JL.** ClinCases Newsletter. Patient Case and Review of a CF Treatment Option that May Modify the Course of Disease. 2017. Available from:  
<https://www.orkambihcp.com/>
7. **Taylor-Cousar, JL.** Cystic Fibrosis Foundation Webcast: New Developments in Drugs to Reduce Infection. 2016. Available from: <https://www.cff.org/CF-Community-Blog/Posts/2016/WATCH-New-Developments-in-Drugs-to-Reduce-Infection-March-2016/>
8. **Taylor-Cousar, JL.** Patient Simulation Video: Communicating with Patients about Mutation based Therapies for CF. *Cystic Fibrosis Care Advancement Program*. 2016. Available from: <http://www.advancesincf.org/podcast>.
9. Nick JA, **Taylor-Cousar JL.** Podcast: Strategies to improve the prevention and treatment of pulmonary exacerbations and infections in the CF patient. *Cystic Fibrosis Care Advancement Program*. 2015. Available from:  
<http://www.advancesincf.org/podcast>.
10. **Taylor-Cousar JL**, Brayshaw S. Podcast: Considerations Related to the Transition from Pediatric to Adult Cystic Fibrosis Care. *Cystic Fibrosis Care Advancement Program*. 2015. Available from: <http://www.advancesincf.org/podcast>.

11. **Taylor-Cousar, JL.** Cystic Fibrosis Foundation Webcast: Lung Transplantation-The Patient Perspective. 2014. Available from: <https://www.cff.org/Life-With-CF/Treatments-and-Therapies/Lung-Transplantation/Surgery-Recovery-and-Life-Post-Transplant/Life-After-a-Lung-Transplant/>
12. **Taylor-Cousar JL.** Expert Insight Article: Diabetes in the Patient with Cystic Fibrosis. *Cystic Fibrosis Care Advancement Program*. 2014. Available from: <http://www.advancesincf.org/expert-insight-articles>
13. **Taylor-Cousar JL.** Webinar: Therapies on the Horizon for CF. *Cystic Fibrosis Care Advancement Program*. 2014. Available from: <http://advancesincf.org/webinar/Webinar3-TaylorC/presentation.html>
14. **Taylor-Cousar JL.** Webinar: Update on CF Mutations. *Cystic Fibrosis Care Advancement Program*. 2014. Available from: <http://advancesincf.org/webinar/Webinar1-TaylorC/presentation.html>
15. Nick JA, **Taylor-Cousar JL**, Brayshaw S, Chacon C. Podcast: Employing a Multidisciplinary Approach to Managing CF Patients. 2014. *Cystic Fibrosis Care Advancement Program*. Available from: <http://advancesincf.org/podcasts/P2P3/presentation.html>
16. Nick JA, **Taylor-Cousar JL**, Brayshaw S, Chacon C. Podcast: Early and Aggressive Treatment of Pulmonary Exacerbations in the CF Patient. *Cystic Fibrosis Care Advancement Program*. 2014. Available from: <http://advancesincf.org/podcasts/P2P2/presentation.html>
17. Nick JA, **Taylor-Cousar JL**, Brayshaw S, Chacon C. Podcast: Transition from Pediatric to Adult Care and Strategies to Improve Adherence to Treatment. *Cystic Fibrosis Care Advancement Program*. 2014. Available from: <http://advancesincf.org/podcasts/P2P1/presentation.html>
18. Nick JA, **Taylor-Cousar JL**, Brayshaw S, Chacon C, Trout C, Rasmussen L. Content development for Interactive Patient Education Platform: Empowering and Educating Patients and Care Givers: Managing Real World Transition Strategies from Adolescence to Adulthood in Cystic Fibrosis. 2014. Available from: <http://visits.propatientlearning.com/visit/nBhQ3ZOHRZ#nBhQ3ZOHRZ>

19. ATS Policy Brief on the Pulmonary, Critical Care and Sleep Workforce (Lead author, **Taylor-Cousar JL**) May 2012. Available from:  
<http://www.thoracic.org/advocacy/policy-position-statements/index.php>

#### D. RECENT SELECTED ABSTRACTS

1. **Taylor-Cousar, JL** and Nash E. Outcomes of CFTR Modulator Use During Pregnancy- An International Survey. 2019 North American CF Conference Nashville, TN
2. **Taylor-Cousar JL**. Initial results evaluating the first in class CFTR amplifier, PTI-428, in subjects with CF on background treatment with tezacaftor/ivacaftor. 2019 North American CF Conference Nashville, TN
3. **Taylor-Cousar JL**, Shive N, Leonhardt A, St. Clair C, Nick JA, Saavedra MT, Lommatzsch S, Lommatzsch S, Everett D. TRANSITION: An observational study of the effects of transition from lumacaftor/ivacaftor to tezacaftor/ivacaftor. Poster Presentation. 2019 European CF Conference. Liverpool, UK
4. **Taylor-Cousar JL**, Jain R, Brown AW, Nash EF. Continuation of dual combination CFTR modulators during pregnancy in women with CF. Oral presentation. 2019 European CF Conference. Liverpool, UK
5. D. Downey, P. Flume, M. Jain, I. Fajac, C. Schwarz, T. Pressler, S. Van Koningsbruggen-Rietschel, **J. Taylor-Cousar**, A. Horsley, S. Sutharsan, J. Miller, G. Poirier, J. Jiang, T. Inoue, S. Wilson, P.-S. Lee, G. Gilmartin. Initial results evaluating combinations of the novel CFTR corrector PTI-801, potentiator PTI-808, and amplifier PTI-428 in cystic fibrosis subjects. Oral presentation. 2019 European CF Conference. Liverpool, UK
6. M. Jain, J. Pilewski, P. Flume, **J. Taylor-Cousar**, S. Rowe, C. Milla, D. Layish, J. Miller, C. Mortelliti, J. Jiang, T. Inoue, S. Wilson, P.-S. Lee<sup>8</sup>, G. Gilmartin. Initial results evaluating the add-on effect of the novel CFTR corrector PTI-801 in cystic fibrosis subjects. Oral presentation. 2019 European CF Conference. Liverpool, UK
7. **Taylor-Cousar JL**, Hunt KC, St Clair C, Everett D, Nick JA, Saavedra MT, Fenster B and Abman SH. A randomized controlled pilot study of sildenafil to treat exercise intolerance in moderate to severe CF. Poster presentation. Thematic Poster Discussion Session: Clinical Care in the Era of CFTR Modulators. 2018 North American CF Conference Denver, CO *Pediatr Pulmonol* 2018; 53, Suppl 2:A212.
8. **Taylor-Cousar JL**, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Roberson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T and Keating D. Phase 2 Safety and Efficacy of the Triple-Combination CFTR Modulator Regimen VX-445/TEZ/IVA in

CF. Oral presentation. Progress in Pulmonary Disease Workshop. 2018 North American CF Conference Denver, CO *Pediatr Pulmonol* 2018; 53, Suppl 2:A213.

9. Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, **Taylor-Cousar JL**, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Uzan F, Young T, and Rowe SM. Triple Combination of VX-659/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. Oral presentation. Progress in Pulmonary Disease Workshop. 2018 North American CF Conference Denver, CO *Pediatr Pulmonol* 2018; 53, Suppl 2:A216.
10. Elborn JS, **Taylor-Cousar JL**, Ahuja S, Springman E, Mershon J, Grosswold R, Rowe SM. A Phase 2 Trial (EMPIRE CF) of a Novel Anti-inflammatory molecule, Acebilustat, in Patients with Cystic Fibrosis. Poster presentation. Thematic Poster Discussion Session: Clinical Care in the Era of CFTR Modulators. 2018 North American CF Conference Denver, CO *Pediatr Pulmonol* 2018; 53, Suppl 2:A214.
11. Yang Y, Rizio A, Chuang CC, Loop B, You P, Kosinski M, Rendas-Bau R, Lekstrom-Himes J, **Taylor-Cousar JL**, Sole A, Elborn JS. Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis and F508del/F508del-CFTR: Patient-reported outcomes in a phase 3 randomized controlled trial (EVOLVE)". Poster presentation. 2018 North American CF Conference Denver, CO *Pediatr Pulmonol* 2018; 53, Suppl 2:A308.
12. Jain M, Flume P, Escobar H. Taylor-Cousar JL, Pressler T, Liou TG, Mortelliti C, Wilson S, Lee P, Gilmartin GS. Initial Results Evaluating Third Generation CFTR Corrector PTI-801 in CF Subjects. 2018 North American CF Conference Denver, CO *Pediatr Pulmonol* 2018; 53, Suppl 2:A261.
13. Godfrey EM, Mody SK, Gilmore KC, Schwartz MR, Jain R, **Taylor-Cousar JL**, Aitken ML, Heltshe S, Sufian S for the Cystic Fibrosis Contraceptive Research Collaborative. Contraception, pregnancy and modulator use among reproductive aged women with cystic fibrosis. Poster presentation. 2018 North American CF Conference Denver, CO *Pediatr Pulmonol* 2018; 53, Suppl 2:A706.
14. **Taylor-Cousar JL**, Hunt KC, St Clair C, Everett D, Nick JA, Saavedra MT, Fenster B and Abman SH. A randomized controlled pilot study of sildenafil to treat exercise intolerance in moderate to severe CF. Oral Presentation. 2018 European CF Conference. Belgrade, Serbia
15. **Taylor-Cousar JL**, Tullis E, Derichs N, Davies J, Nazareth D, Downey DG, Rosenbluth D, Fajac I, Malfroot A, Saunders C, Short C, Jensen R, Solomon GM, Vermeulen F, Willmann S, Saleh D, Langer D, Kaiser A, Hoffmann A, Rowe SM, Ratjen F. Safety, tolerability, and early signs of efficacy with riociguat for the treatment of adult

Phe508del homozygous cystic fibrosis: Efficacy data from the Phase II Rio-CF study. Poster Presentation. 2018 European CF Conference. Belgrade, Serbia

16. Davies J, Colombo C, Tullis E, McKee C, DeSouza C, Waltz D, Savage J, Fisher M, Shilling R, Moskowitz S, Robertson S, Tian S, **Taylor-Cousar JL**, Rowe SM. Preliminary Safety and Efficacy of Triple Combination CFTR Modulator Regimens in CF. Oral Presentation. 2018 European CF Conference. Belgrade, Serbia
17. Tullis E, Columbo C, Davies JC, McKee C, DeSouza C, Waltz D, Savage J, Fisher M, Shilling R, Moskowitz S, Robertson S, Tian S, **Taylor-Cousar JL**, and Rowe SM. Preliminary Safety and Efficacy of Triple Combination CFTR Modulator Regimens in CF. Oral Presentation. 2017 North American CF Conference. Indianapolis, IN.
18. Nick S, **Taylor-Cousar JL**, Nichols DP, Malcolm KC, Ellington S, Lommatzsch S, Kuk K, Grancelli A, Homra J, Lommatzsch S, Saavedra MT and Nick JA. Pulmonary Exacerbations Associated with Viral Infections Result in Longer Duration of Treatment and Worse Outcomes in a Subpopulation of Adult CF Patients. Poster Presentation. North American CF Conference. Indianapolis, IN *Pediatr Pulmonol 2017; 52, Suppl 47: A438*.
19. Saavedra MT, Sanders L, Rsyavy N, Caceres S, Jones C, Pickard K, Malcolm KC, Nichols DP, **Taylor-Cousar JL**, Stand M, and Nick JA. A Peripheral Blood Signature Reflects One Month's Treatment with Inhaled Aztreonam (Cayston®). Poster Presentation. North American CF Conference. Indianapolis, IN *Pediatr Pulmonol 2017; 52, Suppl 47: A418*.
20. Pohl K, Nichols DP, **Taylor-Cousar JL**, Saavedra MT, Nick JA, and Bratcher PE. Clinical and Cellular Markers as Predictors of Lumacaftor/Ivacaftor Treatment Discontinuation. Poster Presentation. 2017 North American CF Conference. Indianapolis, IN. *Pediatr Pulmonol 2017;52, Suppl 47: A309*.
21. Hunt K, St Clair C, Curran-Everett D, Solomon GM, Saavedra MT, Nick JA, Nichols DP and **Taylor-Cousar JL**. CFTR Effects of Oral Sildenafil in Combination with Lumacaftor/Ivacaftor in Adults with CF. Poster Presentation. North American CF Conference. Indianapolis, IN *Pediatr Pulmonol 2017; 52, Suppl 47: A284*.
22. **Taylor-Cousar JL**, Derichs N, Tullis E, Davies JC, Nazareth D, Downey DG, Rosenbluth D, Fajac I, Malfroot A, Bakker M, Wirsching G, Hoffmann A, Rowe SM, Ratjen F. Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: Safety Data From the RIO-CF study. Poster Presentation. 2017 North American CF Conference. Indianapolis, IN. *Pediatr Pulmonol 2017; 52, Suppl 47: A246*.

23. Evans TA, Sharma N, David E, Joynt A, Cutting GR, and **Taylor-Cousar JL**. Identification of a Loss of Function CFTR Variant in Orangutans. *Pediatr Pulmonol* 2017; 52, Suppl 47: A152.
24. Derichs N, **Taylor-Cousar JL**, Tullis E, Davies JC, Nazareth D, Downey DG, Rosenbluth D, Fajac I, Malfroot A, Bakker M, Clancy J, Uluer A, Castellani C, Sermet-Gaudelus I, Ahrens RC, Sutharsan S, Welte T, Gust T, Kaiser A, Hoffmann A, Ratjen F, Rowe SM. Safety, tolerability and early signs of efficacy with riociguat for the treatment of adult Phe508del homozygous cystic fibrosis patients: Study design, rationale for the RIO-CF study. Poster Presentation. 2017 European CF Conference. Seville, Spain.
25. **Taylor-Cousar JL**, Hunt K, Fenster B. Use of Cardiac MRI and Exercise Testing to Characterize RV Mechanics and Exercise Intolerance in Patients with Cystic Fibrosis. Poster Presentation. 2017 American Thoracic Society Conference. Washington, D.C.
26. Liou TG, Adler FR, Brown P, Chatfield BA, Cox DR, Daines C, Elborn JS, Emmett P, Francis J, Jensen JL, Heynekamp TR, Keogh RH, Lechtzin N, Li Y, Lysinger J, Nakamura C, Oliver KN, Packer KA, Quittner AL, Radford P, Szczesniak RD, **Taylor-Cousar JL**, Vroom J and Sagel SD. Mountain West CF Consortium Sputum Biomarker Study. *Pediatr Pulmonol* 2016; Suppl 45: A232.
27. Daines C, Brown P, Chatfield BA, Heynekamp TR, Lysinger J, Nakamura C, Radford P, Sagel SD, **Taylor-Cousar JL**, Quittner AL, Lechtzin N, Keogh RH, Szczesniak RD, Elborn JS, and Liou TG. Depression and Anxiety Associate with Pain and Dyspnea but not FEV1 in the Mountain West. *Pediatr Pulmonol* 2016; Suppl 45: A701.

#### E. PRESENTATIONS AT LOCAL, REGIONAL, NATIONAL AND INTERNATIONAL MEETINGS

##### INTERNATIONAL

- |      |   |
|------|---|
| 2019 | Speaker, Management of Orangutan Respiratory Disease Syndrome<br>BOS Nyaru Menteng Veterinary Group Conference<br>Palangkayara, Indonesia |
| 2019 | Speaker, Respiratory Intensive Care Emergencies<br>Orangutan Veterinary Advisory Group Conference<br>Yogyakarta, Indonesia                |
| 2019 | Session Small Group Leader, Scientific Writing<br>Orangutan Veterinary Advisory Group Conference<br>Yogyakarta, Indonesia                 |

- 2019                      Session Speaker, Pregnancy Outcomes in women with CF  
on CFTR Modulators-an international survey  
New therapies and real life experience  
European Cystic Fibrosis Conference  
Liverpool, U.K.
- 2018                      Speaker, Real world use of Tezacaftor-Ivacaftor  
Vancouver Adult and Pediatric CF Centers  
Vancouver, BC, Canada
- 2018                      Speaker, Bronchiectasis and Sinusitis: Diagnosis and  
Treatment  
BOS Nyaru Menteng Veterinary Group Conference  
Palangkayara, Indonesia
- 2018                      Session leader, Use of the portable bronchoscope  
Practical Application of Diagnostic Tools Workshop  
Orangutan Veterinary Association Group Conference  
Aceh, Indonesia
- 2018                      Speaker, Bronchiectasis and Sinusitis: Diagnosis and  
Treatment  
Management of Respiratory Issues in Captive Orangutans  
Session  
Orangutan Veterinary Association Group Conference  
Aceh, Indonesia
- 2018                      Speaker, Clinical Trials Addressing CF Inflammation  
Breakfast Symposium: Inflammation in Cystic Fibrosis:  
The Next Frontier  
European Cystic Fibrosis Conference  
Belgrade, Serbia
- 2018                      Session Moderator, Meet the Experts: Pregnancy  
European Cystic Fibrosis Conference  
Belgrade, Serbia
- 2018                      Speaker, Management of extrapulmonary complications  
during pregnancy  
Meet the Experts: Pregnancy Session  
European Cystic Fibrosis Conference  
Belgrade, Serbia
- 2018                      Speaker, What is Bronchiectasis: Data from human and  
non-human primates



Royal Brompton and Harefield Hospital  
London, U.K.

- 2018 Speaker, Saving the People of the Forest: one chocolate bar and one nebulizer treatment at a time  
A Trinity Hall Natural Sciences Society Lecture  
University of Cambridge  
Cambridge, U.K.
- 2017 Speaker, Live Webinar: The Orangutan Project  
Consumer Connect  
Australasian Cystic Fibrosis Conference  
Melbourne, Australia
- 2017 Speaker, CF manifestations and changing focus in older patients  
CF: Young and the Aging Symposium  
Australasian Cystic Fibrosis Conference  
Melbourne, Australia
- 2017 Speaker, What is Bronchiectasis  
The basic defect - models and molecules Symposium  
Australasian Cystic Fibrosis Conference  
Melbourne, Australia
- 2017 Speaker, Clinical Trials and Drug Discovery  
Lay Conference Symposium  
Australasian Cystic Fibrosis Conference  
Melbourne, Australia
- 2017 Speaker, Clinical Trial and Real World Experience with Lumacaftor/Ivacaftor  
Regional Seminar  
Brisbane, Australia
- 2017 Speaker, CFTR Genetics in Orangutans  
Orangutan Veterinary Association Group  
Yogyakarta, Indonesia
- 2017 Speaker, The U.S. Experience with Orkambi  
Montreal Regional Symposium  
Montreal, Canada
- 2017 Speaker, The U.S. Experience with Orkambi  
London Regional Symposium: Orkambi, the Next Precision Medicine for CF

London, England

- 2016 Speaker, Genetic and phenotypic characterization of chronic airway disease in orangutans  
Great Ape Medicine Seminar  
Melaka, Malaysia
- 2016 Speaker, Interpretation of Thoracic Radiographs  
Great Ape Medicine Seminar  
Melaka, Malaysia
- 2016 Speaker, Orkambi-Real World Experience  
North of Scotland Paediatric Respiratory Network Conference  
Dundee, Scotland
- 2016 Speaker, The U.S. Experience with Orkambi  
Regional Symposium: Orkambi, the Next Precision  
Medicine for CF  
Newmarket, England
- 2016 Speaker, Genetic and phenotypic characterization of chronic airway disease in non-human primates  
Orangutan Veterinary Association Group Workshop  
Sabah, Malaysia
- 2016 Speaker, Interpretation of Thoracic Radiographs  
Orangutan Veterinary Association Group Workshop  
Sabah, Malaysia

#### NATIONAL

- 2019 Session Chair and Speaker, Work Life Balance: Recharging for Success  
Cystic Fibrosis Foundation Career Development Retreat  
Ellicott City, MD
- 2019 Speaker, Project Update: Improving the Management of Chronic Respiratory Disease in Captive Bornean Orangutans (*Pongo Pygmaeus*) Utilizing Cystic Fibrosis Therapies In an Orangutan Rehabilitation Program In East Kalimantan, Indonesia  
Orangutan Husbandry Conference  
Fort Wayne, IN
- 2019 Speaker, Restoration of CFTR Function for >90% of People with CF

- Session 1: Current Landscape of CFTR Modulators  
Cystic Fibrosis Foundation Research Conference: Pushing  
the Frontiers  
Stowe, VT
- 2019 Co-Chair, Symposium: Cystic Fibrosis: Heterogeneity in a  
Monogenic Disease  
American Thoracic Society International Conference  
Dallas, TX
- 2019 Speaker, Use of CFTR Modulator during Pregnancy  
Mountain West CF Consortium Conference  
Las Vegas, NV
- 2019 Speaker, Success in Academic Medicine  
CF TDN Spring Meeting  
Austin, TX
- 2019 Speaker, Inflammation in CF: Friend or Foe  
ResearchCon by the Cystic Fibrosis Foundation  
Webinar
- 2019 Speaker, CF Reproductive and Sexual Health Committee  
(CFReSHC) Patient Task Force Meeting  
CFTR Modulators and their Impact on Sexual and  
Reproductive Health  
Webinar
- 2018 Speaker, Pulmonary Grand Rounds  
Cystic Fibrosis Therapeutics: Great Strides and Future  
Directions  
University of Pennsylvania  
Philadelphia, PA
- 2018 Co-Chair, Thematic Poster Discussion Session  
Clinical Care in the Era of CFTR Modulators  
North American CF Conference  
Denver, CO
- 2018 Speaker, Developing CFTR Modulators in an Era of Highly  
Effective Modulators.  
Plenary Session: Clinical Trials in the Setting of Existing  
Therapies  
CF Therapeutics Development Meeting  
North American CF Conference  
Denver, CO

- 2018 Speaker, Improving the Management of Chronic Respiratory Disease in Captive Bornean Orangutans (*Pongo Pygmaeus*) Utilizing Cystic Fibrosis Therapies In an Orangutan Rehabilitation Program In East Kalimantan, Indonesia  
Orangutan Husbandry Conference  
Kansas City, MO
- 2018 Speaker, Improving the Quality of Life in Patients with CF Through CFTR Modulation  
From Principles to Practice: Exploring Mechanistic Knowledge to Advance Clinical Care  
American Thoracic Society International Conference  
San Diego, CA
- 2018 Speaker, Success in Academic Medicine  
CF TDN Spring Meeting  
Philadelphia, PA
- 2017 Speaker, Chronic Respiratory Disease in Orangutans: Signs, Symptoms and Search for a Cause  
Gilead Pharmaceuticals Noon Symposium  
San Francisco, CA
- 2017 Co-Chair, Symposium: CF Interventions Advancing Through the Clinical Testing Phase  
North American CF Conference  
Indianapolis, IN
- 2017 Speaker, Advances in Treating Patients Homozygous for 508del  
CF Interventions Advancing Through the Clinical Testing Phase Symposium  
North American CF Conference  
Indianapolis, IN
- 2017 Speaker, Update on Cystic Fibrosis Science: From the Gene to the Patient  
Live CME Seminar at NACFC 2017 Titled, "The Emerging Role of CFTR Combination Regimens in Improving Outcomes for Patients with Cystic Fibrosis  
North American CF Conference  
Indianapolis, IN

- 2017 Speaker, Co-partnering in Transitioning to Adult an Adult Center  
Psychosocial Collaborative Seminar  
North American CF Conference  
Indianapolis, IN
- 2017 Speaker, Veterinary Panel  
Orangutan Husbandry Conference  
New Orleans, LA
- 2017 Speaker, Signs, Symptoms and Searching for a Cause of Orangutan Lung Disease  
Orangutan Husbandry Conference  
New Orleans, LA
- 2017 Speaker, Lung Transplant  
CF Education Night  
National Jewish Health  
Denver, CO
- 2017 Co-Chair, Mini-Symposium  
Advances in Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis  
American Thoracic Society International Conference  
Washington, D.C.
- 2017 Facilitator, Thematic Poster Session  
Mechanisms in Cystic Fibrosis and Other Bronchiectatic Diseases  
American Thoracic Society International Conference  
Washington, D.C.
- 2017 Speaker, Cystic Fibrosis: Looking Toward New Treatments on the Horizon  
National Rare Lung Disease Patient Education Day  
Cystic Fibrosis Foundation/American Thoracic Society  
New York, NY
- 2017 Moderator, Parade of PIs  
CF Therapeutics Development Network Spring Conference  
Nashville, TN
- 2017 Speaker, Inflammation in CF  
CF Family Education Day  
St. Luke's Medical Center  
Boise, ID

- 2017 Speaker, National Jewish Health Trustees and Friends Forum, Southern Region  
CF Clinical Care and Research  
Boca Raton, FL
- 2016 Speaker, Veterinary Panel  
Orangutan Husbandry Workshop  
Madison, WI
- 2016 Speaker, Research Update: Genetic and phenotypic characterization of chronic airway disease in non-human primates  
Orangutan Husbandry Workshop  
Madison, WI
- 2016 Speaker, Inflammation in CF: Friend or Foe?  
Cystic Fibrosis Research Institute Conference  
Redwood City, CA
- 2016 Speaker, Clinical Year in Review Session 1  
Update on Cystic Fibrosis  
American Thoracic Society International Conference  
San Francisco, CA
- 2016 Co-Moderator, Mini-Symposium  
Refining the Evaluation and Treatment of Cystic Fibrosis  
American Thoracic Society International Conference  
San Francisco, CA
- 2016 Co-Moderator, Clinical Year in Review Sessions  
American Thoracic Society International Conference  
San Francisco, CA
- 2016 Session Chair/speaker, Parade of PIs  
CF Therapeutics Development Spring Meeting  
San Antonio, TX
- 2016 Featured speaker, CFF Interview  
New Developments in Drugs to Reduce Infection  
<https://www.cff.org/CF-Community-Blog/Posts/2016/WATCH-New-Developments-in-Drugs-to-Reduce-Infection-March-2016/>
- 2016 Speaker, Update in Cystic Fibrosis  
Advanced Lung Disease Symposium

St. Joseph's Hospital and Medical Center/Norton Thoracic Institute  
Phoenix, AZ

- 2015 Speaker, Veterinary Panel  
Orangutan Husbandry Workshop  
Wichita, KS
- 2015 Co-Moderator, Workshop: CF Airway Inflammation,  
Biomarkers  
& Therapeutic Targets  
North American CF Conference  
Phoenix, AZ
- 2015 Co-Moderator, Workshop: Genetics, Genomics & Big Data  
Sets  
North American CF Conference  
Phoenix, AZ
- 2015 Speaker, Cystic Fibrosis Therapeutics: Great Strides and  
Future Directions  
Internal Medicine Grand Rounds  
Duke University  
Durham, NC
- 2015 Speaker, Live Webinar  
Cystic Fibrosis and Lung Transplant: A Discussion with a  
Physician and a Transplant Recipient  
Cystic Fibrosis Week at the ATS
- 2015 Co-Moderator, Session: Insights from Clinical CFTR  
Modulation  
CFF Research Conference: Pushing the Frontiers  
Chantilly, Virginia
- 2015 Speaker, Insights from Clinical CFTR Modulation Session  
Ivacaftor in Advanced CF Lung Disease  
CFF Research Conference: Pushing the Frontiers  
Chantilly, Virginia
- 2015 Speaker, Update on Clinical Trials and Novel Therapy in  
CF  
Mountain West CF Consortium Conference  
Denver, CO
- 2014 Speaker, Research Symposium

- Genetic and phenotypic characterization of chronic airway disease in non-human primates  
Orangutan Husbandry Workshop  
Fort Worth, TX
- 2014 Speaker, Veterinary Panel  
Orangutan Husbandry Workshop  
Fort Worth, TX
- 2014 Co-Moderator, Clinical Year in Review Sessions 1-4  
American Thoracic Society International Conference  
San Diego, CA
- 2014 Co-Chair, Symposium: Beyond Routine Care and Exacerbations: Challenges and Considerations in the Management of Cystic Fibrosis  
American Thoracic Society International Conference  
San Diego, CA
- 2014 Co-Moderator, Poster Discussion Session  
You Only Live Twice: Donor and Allocation Issues in Lung Transplant  
American Thoracic Society International Conference  
San Diego, CA
- 2014 Speaker, Evaluation of the Adult with Bronchiectasis: Could This Be CF?  
American Thoracic Society International Conference  
San Diego, CA
- 2014 Speaker, Sunrise seminar  
Diagnosis and Evaluation of Adults with CF  
American Thoracic Society International Conference  
San Diego, CA
- 2014 Speaker, Management of Older Adults with CF Workshop  
Cardiovascular Disease in Adults with CF  
American Thoracic Society International Conference  
San Diego, CA
- 2014 Speaker, Invited Guest Lecture  
Upper and Lower Airway Disease in Human and Non-Human Primates  
Great Apes Center, Wauchula, FL
- 2013 Speaker, National CF Education Day



- Transplant: Things a Person with CF Should Know  
Cystic Fibrosis Foundation/American Thoracic Society  
National broadcast from Denver, CO
- 2013 Co-Chair, Mini Symposium: Therapeutic and Diagnostic  
Advances in Cystic Fibrosis  
American Thoracic Society International Conference  
Philadelphia, PA
- 2013 Speaker, Therapeutic and Diagnostic  
Advances in Cystic Fibrosis Mini Symposium  
Oral Sildenafil Reduces Airway Inflammation in Adults with CF  
American Thoracic Society International Conference  
Philadelphia, PA
- 2013 Co-Chair Poster Discussion Session: CF: New Insights into Airway  
Infection and Inflammation  
American Thoracic Society International Conference  
Philadelphia, PA
- 2012 Co-Facilitator, Thematic Poster Session: Pathogenesis and  
Clinical Issues in Cystic Fibrosis  
American Thoracic Society International Conference  
San Francisco, CA
- 2011 Speaker, CF Education Day  
What's New in CF Clinical Research  
University of Mississippi  
Jackson, MS
- 2011 Cystic Fibrosis Foundation Webcast: Patient Perspective on Lung  
Transplant  
<http://media.newsinfusion.com/LungTransplantation/>
- 2011 Co-Chair, Poster Discussion Session:  
Adult Cystic Fibrosis: Advances in Treatment and Understanding  
Of Mechanisms of Disease  
American Thoracic Society International Conference  
Denver, CO
- 2011 Speaker, Pulmonary Session  
“Adult Diagnosis of CF: Mild or Delayed Onset Disease”  
Western Regional Meeting  
Carmel, CA
- 2011 Co-Moderator, Pulmonary and Critical Care Session

- Western Regional Meeting  
Carmel, CA
- 2010 Co-Moderator, Workshop: Emerging Strategies & Clinical Progress in CF Therapeutics  
North American Cystic Fibrosis Conference  
Baltimore, MD
- 2010 Co-Moderator, Round table: Potentiators and Activators in the Pipeline  
North American Cystic Fibrosis Conference  
Baltimore, MD
- 2010 Speaker, Meet the Professor  
Update in Cystic Fibrosis  
American Thoracic Society International Conference  
New Orleans, LA
- 2010 Co-Chair, Poster Discussion Session: Advances in Cystic Fibrosis  
American Thoracic Society International Conference  
New Orleans, LA
- 2009 Speaker, Physicians' Grand Rounds  
Evaluation and Management of Exercise Intolerance in a Patient With CF  
North American Cystic Fibrosis Foundation Conference  
Minneapolis, MN
- 2009 Facilitator, Thematic Poster Session: Adult Cystic Fibrosis  
American Thoracic Society International Conference  
San Diego, CA
- 2007 Moderator, Asthma and Cystic Fibrosis roundtable  
North American Cystic Fibrosis Foundation Conference  
Anaheim, CA
- 2005 Presenter, Case Presentation: Chronic Granulomatous Disease  
Pediatric Clinical Images Session  
American Thoracic Society International Conference
- 2004 Speaker, Case Presentation: Lymphangiomyomatosis  
Chest Radiology Session  
American College of Chest Physicians Conference
- 2003 Speaker, Chronic Pain in Cystic Fibrosis

Fellows Symposium  
North American Cystic Fibrosis Foundation Conference

LOCAL/REGIONAL

- 2019 Speaker, Internal Medicine Grand Rounds  
Cystic Fibrosis Therapeutics: Great Strides and Future Directions  
National Jewish Health  
Denver, CO
- 2018 Speaker, Internal Medicine Grand Rounds  
Cystic Fibrosis Therapeutics: Great Strides and Future Directions  
University of Colorado  
Aurora, CO
- 2018 Speaker, CF Disease State Training  
Overview of Cystic Fibrosis  
Office of Professional Education  
National Jewish Health
- 2018 Speaker, CF Disease State Training  
CFTR Modulators  
Office of Professional Education  
National Jewish Health
- 2018 Key Note Speaker, History and Success of the CF TDN  
CF Celebrity Golf Reunion  
Castle Rock, CO
- 2018 Update on CF  
Department of Medicine Grand Rounds  
Saint Joseph Hospital  
Denver, CO
- 2018 Speaker, Saving the People of the Forest: one chocolate bar  
and one nebulizer treatment at a time  
Clinical Research Professionals Day  
National Jewish Health
- 2018 Speaker, Adult and Pediatric Cystic Fibrosis  
40<sup>th</sup> Annual Pulmonary and Allergy Update  
Keystone, CO
- 2018 Speaker, Adult and Pediatric Cases

- 40<sup>th</sup> Annual Pulmonary and Allergy Update  
Keystone, CO
- 2017      Featured Interview, Partnering with the Zoo for Respiratory  
Care of Primates  
Denver Zoo Website  
<https://www.youtube.com/watch?v=8RdR1idAOoM&feature=youtu.be>
- 2016      Speaker, Cystic Fibrosis Clinical Year in Review  
Internal Medicine Grand Rounds  
National Jewish Health  
Denver, CO
- 2016      Keynote Speaker, Adult Issues in Cystic Fibrosis  
Colorado CF Chapter Annual Meeting  
Denver, CO
- 2015      Speaker, Cystic Fibrosis Clinical Care and Research  
SJH Internal Medicine Residency Conference  
Saint Joseph Hospital  
Denver, CO
- 2015      Speaker, Introduction to Cystic Fibrosis  
Office of Development  
National Jewish Health  
Denver, CO
- 2015      Co-Moderator, Symposium: Here Comes the Sun: Clinical  
Manifestations and Prognosis in Adult Cystic Fibrosis  
American Thoracic Society International Conference  
Denver, CO
- 2015      Co-Moderator, Clinical Year in Review Sessions  
American Thoracic Society International Conference  
Denver, CO
- 2015      Speaker, CF Symposium  
CF Update: CFTR Directed Therapies  
National Jewish Health 37<sup>th</sup> Annual Pulmonary and Allergy  
Update  
Keystone, CO
- 2015      Speaker, CF Workshop  
Cystic Fibrosis Cases  
National Jewish Health 37<sup>th</sup> Annual Pulmonary and Allergy

- Update  
Keystone, CO
- 2014 Speaker, Pulmonary Research in Progress Conference  
Genetic and phenotypic characterization of chronic airway  
disease in non-human primates  
National Jewish Health  
Denver, CO
- 2014 Speaker, Brown Bag Conference  
Upper and Lower Airway Disease in Human and Non-Human  
Primates  
Denver Zoo
- 2014 Speaker, Hopes for a Patient with CF  
National Jewish Health Beaux Arts Ball  
Denver, CO
- 2013 Speaker, Pulmonary Fellows' Education Day  
Lung Transplant and Non-Pulmonary Complications in Cystic  
Fibrosis  
University of Colorado Aurora, CO
- 2012-2013 Speaker, CF Clinical and Translational Research at NJH  
Clinical and Translational Research Conference  
National Jewish Health  
Denver, CO
- 2012 Speaker, Lung MRI Imaging in CF: A New Outcome Measure for  
Clinical Care and Clinical Research?  
Radiology Conference  
National Jewish Health  
Denver, CO
- 2012 Speaker, CF Clinical Research: Challenges and Updates  
Pediatric Pulmonary Fellows' Conference  
National Jewish Health  
Denver, CO
- 2011-2012 Speaker, Cystic Fibrosis Advanced Disease State  
Training Symposium  
National Jewish Health  
Denver, CO
- 2011 Speaker, Lung MRI Imaging in CF: A New Outcome  
Measure for

- Clinical Care and Clinical Research?  
Pulmonary Research in Progress Conference  
National Jewish Health  
Denver, CO
- 2011 Speaker, Role of Phosphodiesterase Inhibitors in CF Lung Disease  
Pediatric Pulmonary Fellows' Conference  
National Jewish Health  
Denver, CO
- 2008 Speaker, Dr. Paul Di Sant' Agnese Physician, Scientist, Pioneer  
Clinical and Translational Science Conference  
University of New Mexico  
Albuquerque, NM
- 2008 Speaker, Infectious Disease Fellows' Conference  
CF Microbiology  
University of New Mexico  
Albuquerque, NM
- 2007-2008 Speaker, How to Apply for Residency  
University of New Mexico MWIM Conference  
Albuquerque, NM
- 2007 Speaker, CF Management and Microbes: The Old and New  
New Mexico Thoracic Society Conference  
Albuquerque, NM
- 2007 Speaker, From Orphan Disease to Model for Multidisciplinary Care: The  
History of Cystic Fibrosis  
Clinical and Translational Science Conference  
University of New Mexico Albuquerque, NM
- 2006-2009 Speaker, Adult CF  
Internal Medicine Residents' Conference  
University of New Mexico
- 2006-2009 Speaker, Adult CF and Pulmonary Complications of Severe  
CF Lung Disease  
Pulmonary Fellows' Conference  
University of New Mexico Albuquerque, NM
- 2006-2007 Speaker, Cystic Fibrosis Foundation Gala  
Albuquerque, NM

2003 Speaker, 2003 National Cystic Fibrosis Conference Summary  
Clinical Review Conference  
Duke University Medical Center Durham, NC

#### F. LAY PRESS COVERAGE

1. Orangutan CT Scan featured in Series 1.2 of Big Animal Surgery series. 2019. BBC <https://www.bbc.co.uk/iplayer/episode/m0005hpw/ad/big-animal-surgery-series-1-2-chimpanzee>
2. Three-drug combination improves life for cystic fibrosis patients. 2018. *NBC News*. Available from: <https://www.nbcnews.com/health/health-news/three-drug-combination-improves-life-cystic-fibrosis-patients-n921671>
3. New therapies pack a triple-drug punch to treat cystic fibrosis. 2018. *Science News*. Available from: <https://www.sciencenews.org/article/new-therapies-pack-triple-drug-punch-treat-cystic-fibrosis>
4. Triple Therapy for CF. 2018. *The HealthCare Channel*. Available from: <https://www.youtube.com/watch?v=CPoMEFkRtZA>
5. Vertex Lung Drugs Show Promise. 2017. *The Wall Street Journal*. Available from: <https://www.wsj.com/articles/vertex-reports-positive-data-for-new-cystic-fibrosis-drugs-1500408300>
6. Vertex Picks ‘Impressive Cystic Fibrosis Drugs to Aim for A Multibillion-Dollar Market. 2017. *Forbes*. Available from: <https://www.forbes.com/sites/matthewherper/2018/01/31/vertex-picks-impressive-cystic-fibrosis-drugs-to-aim-for-a-multibillion-dollar-market/#3e18ff9f3d23>
7. Tezacaftor-ivacaftor, ivacaftor alone Effective in CF. 2017. *HealthDay*. Available from: <https://www.forbes.com/sites/matthewherper/2018/01/31/vertex-picks-impressive-cystic-fibrosis-drugs-to-aim-for-a-multibillion-dollar-market/#3e18ff9f3d23>
8. Tezacaftor/Ivacaftor Combo Show Positive Results in CF Patients. *Cystic Fibrosis News Today*. 2017. Available from: <https://www.forbes.com/sites/matthewherper/2018/01/31/vertex-picks-impressive-cystic-fibrosis-drugs-to-aim-for-a-multibillion-dollar-market/#3e18ff9f3d23>
9. Phase 3 Studies of the Tezacaftor/Ivacaftor Combination Treatment in People with Cystic Fibrosis Ages 12 and Older Published in the *New England Journal of Medicine*.

2017. *Business Wire*. Available from:

<https://www.forbes.com/sites/matthewherper/2018/01/31/vertex-picks-impressive-cystic-fibrosis-drugs-to-aim-for-a-multibillion-dollar-market/#3e18ff9f3d23>

10. Nebulizer Helps Denver Zoo Orangutan Live a Better Life. 2011. CBS Denver.

Available from: <https://denver.cbslocal.com/2011/04/13/nebulizer-helps-denver-zoo-orangutan-live-a-better-life/>

#### G. CONSULTANT AND ADVISORY BOARD WORK WITH THE PHARMACEUTICAL INDUSTRY

Vertex, Genentech, Gilead, Novartis, Proteostasis, Protalix, Celtaxys, Santhera

- |       |  |
|-------|--|
| 2018- | Member, Therapeutics Clinical Strategy Steering Committee (Santhera)                                     |
| 2018- | Chair, PTI-428 Phase III Development Steering Committee (Proteostasis Therapeutics)                      |
| 2018- | Member, Therapeutics Clinical Strategy Steering Committee (Proteostasis Therapeutics)                    |
| 2017- | Co-Chair, Next Generation CFTR Modulator Development Program Steering Committee (Vertex Pharmaceuticals) |